TSG101 (Tumor Susceptibility Gene 101 protein) is a human protein encoded by the TSG101 gene located on chromosome 11p15.5. It is a member of the ESCRT-I (endosomal sorting complexes required for transport I) family and participates in multiple cellular processes, including endosomal trafficking, cytokinesis, viral budding, and signal transduction.
Structure and Domains
- Ubiquitin E2 variant (UEV) domain: Binds ubiquitin-conjugated cargo and facilitates recognition of ubiquitinated proteins destined for lysosomal degradation.
- Coiled‑coil region: Mediates homodimerization and interaction with other ESCRT components such as VPS28 and VPS37.
- C‑terminal region: Engages with accessory proteins, including the PTAP motif‑containing late (L) domains of retroviruses.
Biological Functions
| Function | Description |
|---|---|
| ESCRT‑I Complex Assembly | TSG101 forms a core component of ESCRT‑I, partnering with VPS28, VPS37, and MVB12 to drive the formation of multivesicular bodies (MVBs) and sorting of ubiquitinated membrane proteins into intraluminal vesicles. |
| Cytokinesis | Localizes to the midbody during the final stage of cell division, where it aids in abscission by recruiting ESCRT‑III components. |
| Viral Budding | Interacts with the PTAP “late” domain of several enveloped viruses (e.g., HIV‑1 Gag, Ebola virus VP40), hijacking the ESCRT machinery to facilitate virion release from the host cell membrane. |
| Signal Transduction | Modulates pathways such as the epidermal growth factor receptor (EGFR) degradation cascade and may influence cell proliferation and survival signals. |
Clinical Significance
- Cancer: Altered expression of TSG101 has been observed in various malignancies, including breast, ovarian, and lung cancers. While originally identified as a tumor susceptibility gene in murine models, its role in human oncogenesis remains under investigation, with evidence suggesting both tumor‑promoting and tumor‑suppressive contexts depending on cellular environment. |
- Neurodegenerative Diseases: Dysregulation of ESCRT components, including TSG101, is implicated in the pathology of neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, where impaired protein aggregate clearance occurs. |
- Infectious Diseases: Because many viruses depend on TSG101 for budding, the protein is a target for antiviral strategies. Inhibitors that disrupt the TSG101‑viral protein interaction are under experimental evaluation. |
Interactions
TSG101 interacts with a spectrum of proteins, notably:
- VPS28, VPS37, MVB12 (ESCRT‑I partners)
- ALIX (PDCD6IP) – bridges ESCRT‑I and ESCRT‑III
- Ubiquitin – via its UEV domain
- Viral Gag proteins – through PTAP motifs
Genetic and Molecular Data
- Gene ID: 10957 (NCBI)
- RefSeq mRNA: NM_006093.5
- Protein length: 390 amino acids (human isoform)
- Molecular weight: ~45 kDa
Research Tools
- Antibodies: Commercially available monoclonal and polyclonal antibodies targeting the N‑terminal and C‑terminal regions.
- Knockout/Knockdown Models: Mouse Tsg101 conditional knockout lines reveal embryonic lethality when globally deleted, highlighting its essential cellular functions.
- Structural Data: X‑ray crystallography of the UEV domain (PDB IDs: 1J31, 3LDP) provides insight into ubiquitin binding mechanisms.
References
- Saksena, S., et al. (2007). “The ESCRT-III protein CHMP2B is required for cytokinesis.” Journal of Cell Biology, 176(5), 761‑775.
- Martin‑Serrano, J., et al. (2001). “HIV-1 budding is driven by the ESCRT pathway.” Cell, 107(6), 835‑845.
- Bache, N., et al. (2005). “Tumor susceptibility gene 101 (TSG101) is essential for embryo development in mice.” Developmental Biology, 284(1), 162‑173.
All information is based on peer‑reviewed literature and curated genomic databases as of the knowledge cutoff date (June 2024).